AKT1 and breast cancer: Overall, the clinical benefits of Akt-ERK dual inhibition by ACN (Figure 3B and Figure 4A,B) as well as downregulation of the Src signaling pathway confirm our hypothesis that ACN has BC anti-invasive activity and may be promising as a dietary complementary therapy to treat TNBC.